Lophius Biosciences Achieves First Clinical Proof of Principle for T-Track® TB for Detection of Active Tuberculosis

Lophius Biosciences, a leader in the field of novel T cell based diagnostic test systems, has announced that it has successfully concluded the first clinical Proof of Principle study for detection of active tuberculosis (TB). The study used its novel T-Track® TB test which is based on Lophius Biosciences proprietary Reverse T Cell Technology (RT Technology).

The clinical Proof of Principle was concluded in India with a cohort of 44 patients. Results demonstrate that the T-Track® TB test was able to detect active TB in 10 of 12 non-treated patients. Besides its high sensitivity and specificity the T-Track® TB test also demonstrated a remarkably short turnaround time of 2 days which compares favorably to currently used classical detection methods. These results imply that the T-Track® TB test could represent an innovative and fast detection approach for this area of strong medical need.

For further test development Lophius Biosciences has been awarded research funding of €140,000 under the scope of the ZIM-solo-program from the German government. This funding should help to broaden the scope of the T-Track® TB tests with respect to detection of latent TB and potential patient-monitoring of treated TB subjects. The company will present first results at Medica next week (14th -17th November 2012) in Düsseldorf.

"We are very pleased to have accomplished clinical Proof of Principle for our second proprietary technology platform. Our short-term goal is geared towards test optimization and further validation in a bigger patient cohort" said Dr. Michael Lutz, CEO of Lophius Biosciences.